Published • loading... • Updated
NIH Mitragynine Opioid Treatment 2026 Trial Clears FDA
Summary by Globalnewspakistan
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NIH Mitragynine Opioid Treatment 2026 Trial Clears FDA
Washington (GNP): NIH Mitragynine Opioid Treatment 2026 research has reached a landmark milestone, as the National Institutes of Health announced that its Investigational New Drug application for mitragynine — the primary psychoactive compound found in the kratom plant — has taken effect with the United States Food and Drug Administration. The development paves the way for the first-ever human clinical trial to evaluate mitragynine as a potentia…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
